PM: DHL übernimmt SDS Rx und stärkt damit seine Kompetenzen im Bereich Life Sciences und Healthcare / PR: DHL Agrees to Acquire SDS Rx Expanding Its Life Sciences and Healthcare Capabilities
mehr
Storys zum Thema Pharmaindustrie
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
mehrTechnische Universität München
Slime as a material for multifunctional spheres
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Hollow microparticles for cargo molecules Slime as a material for multifunctional spheres - Hollow microspheres for molecular cargoes combine multiple functions - They adhere effectively to soft tissue and cartilage - Potential future applications in osteoarthritis or for oral ulcers Researchers at the Technical University of Munich (TUM) have developed hollow microspheres made ...
mehrGrünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
mehrUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
mehrPress release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
Ein Dokumentmehr
- 3
New pharmaceutical spray dryer for OEB-5 containment
mehr Cannovum Health welcomes new strategic majority investor – Triple Crown Ventures becomes main shareholder
mehrCroma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Leobendorf, Austria (ots/PRNewswire) - Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture ...
mehrABDA Bundesvgg. Dt. Apothekerverbände
Germany’s pharmacies under pressure: Statistical Yearbook 2025 now available
Berlin (ots) - ABDA – Federal Union of German Associations of Pharmacists has released the Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2025”. The publication offers a comprehensive overview of the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond. It shows that the number of pharmacies has decreased again. At the ...
mehrIchnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...
mehrLTS Lohmann Therapie-Systeme AG
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality ...
mehr
- 3
Key technology for bioprocesses
mehr Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
mehrMaren Thurow starts as new Head Global Communications at Grünenthal
mehrBiomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase
Vienna, Austria (ots) - Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a ...
mehrBiomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site
mehrAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
mehr
Centor Launches Smart Pill Organizer to Support Medication Adherence
mehrGerresheimer: Bormioli Pharma boosts revenues and earnings
Düsseldorf (ots) - - Revenues +11.6%, Adjusted EBITDA +13.1% - Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% - Q1 significantly influenced by revenue shift in syringe business - Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of 22% Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and ...
mehrFinancial Year 2024: Weleda Achieves Record Turnover and Significantly Improves Profitability
mehrSHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market
mehr- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
Ein Dokumentmehr Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
mehr
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
mehrLTS Lohmann Therapie-Systeme AG
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships
mehrGrünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
mehrNorgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
mehrLAUDA DR. R. WOBSER GMBH & CO. KG
Antonio Manconi Ten Years With LAUDA Italia
mehrRHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
mehr
Vorherige123456Nächste